Abstract Background: Glioblastoma (GB) is the most common and aggressive primary brain tumor in adults. Tumor recurrence occurs in most cases, typically within 2 cm of the resection margin, despite chemo and radiotherapy. This highly invasive nature and the marked heterogeneity of the tumor microenvironment make it challenging to treat. Fluorescence-guided multiple sampling of patient samples is being used to study intra-tumor heterogeneity. In this study we combined mass spectrometry imaging (MSI) with multiplex immunofluorescence (mIF) and histology to identify new therapeutic vulnerabilities based on spatial tumor biology. We developed a same slide workflow applying all 3 technologies to the same section to identify functional lipids that can be manipulated as less toxic therapeutic options. Methods: Twenty GB patients underwent craniotomies and tumor tissue was surgically resected from multiple different fluorescing and non-fluorescing brain locations. MSI was carried out using a Bruker Solarix FTICR mass spectrometer, the same section then underwent mIF for cell and organelle phenotyping, followed by H Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 805.
Ponzoni et al. (Fri,) studied this question.